vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $183.1M, roughly 1.4× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 1.4%, a 12.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -9.4%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $8.7M). Over the past eight quarters, Smith Douglas Homes Corp.'s revenue compounded faster (17.3% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
AMPH vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $260.4M |
| Net Profit | $24.4M | $3.5M |
| Gross Margin | 46.8% | 19.9% |
| Operating Margin | 19.4% | 6.5% |
| Net Margin | 13.3% | 1.4% |
| Revenue YoY | -1.8% | -9.4% |
| Net Profit YoY | -35.7% | -14.3% |
| EPS (diluted) | $0.51 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $260.4M | ||
| Q3 25 | $191.8M | $262.0M | ||
| Q2 25 | $174.4M | $223.9M | ||
| Q1 25 | $170.5M | $224.7M | ||
| Q4 24 | $186.5M | $287.5M | ||
| Q3 24 | $191.2M | $277.8M | ||
| Q2 24 | $182.4M | $220.9M | ||
| Q1 24 | $171.8M | $189.2M |
| Q4 25 | $24.4M | $3.5M | ||
| Q3 25 | $17.4M | $2.1M | ||
| Q2 25 | $31.0M | $2.4M | ||
| Q1 25 | $25.3M | $2.7M | ||
| Q4 24 | $38.0M | $4.1M | ||
| Q3 24 | $40.4M | $5.3M | ||
| Q2 24 | $37.9M | $3.6M | ||
| Q1 24 | $43.2M | $3.0M |
| Q4 25 | 46.8% | 19.9% | ||
| Q3 25 | 51.4% | 21.0% | ||
| Q2 25 | 49.6% | 23.2% | ||
| Q1 25 | 50.0% | 23.8% | ||
| Q4 24 | 46.5% | 25.5% | ||
| Q3 24 | 53.3% | 26.5% | ||
| Q2 24 | 52.2% | 26.7% | ||
| Q1 24 | 52.4% | 26.1% |
| Q4 25 | 19.4% | 6.5% | ||
| Q3 25 | 13.2% | 6.6% | ||
| Q2 25 | 24.2% | 7.7% | ||
| Q1 25 | 21.9% | 8.7% | ||
| Q4 24 | 24.2% | 10.4% | ||
| Q3 24 | 29.8% | 14.2% | ||
| Q2 24 | 30.3% | 11.7% | ||
| Q1 24 | 27.9% | 11.3% |
| Q4 25 | 13.3% | 1.4% | ||
| Q3 25 | 9.0% | 0.8% | ||
| Q2 25 | 17.8% | 1.1% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 1.4% | ||
| Q3 24 | 21.1% | 1.9% | ||
| Q2 24 | 20.8% | 1.7% | ||
| Q1 24 | 25.1% | 1.6% |
| Q4 25 | $0.51 | $0.39 | ||
| Q3 25 | $0.37 | $0.24 | ||
| Q2 25 | $0.64 | $0.26 | ||
| Q1 25 | $0.51 | $0.30 | ||
| Q4 24 | $0.74 | $0.50 | ||
| Q3 24 | $0.78 | $0.58 | ||
| Q2 24 | $0.73 | $0.40 | ||
| Q1 24 | $0.81 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $12.7M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $86.7M |
| Total Assets | $1.6B | $557.6M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $12.7M | ||
| Q3 25 | $276.2M | $14.8M | ||
| Q2 25 | $231.8M | $16.8M | ||
| Q1 25 | $236.9M | $12.7M | ||
| Q4 24 | $221.6M | $22.4M | ||
| Q3 24 | $250.5M | $23.7M | ||
| Q2 24 | $217.8M | $17.3M | ||
| Q1 24 | $289.6M | $32.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $86.7M | ||
| Q3 25 | $776.7M | $82.2M | ||
| Q2 25 | $757.5M | $80.0M | ||
| Q1 25 | $751.3M | $76.9M | ||
| Q4 24 | $732.3M | $73.6M | ||
| Q3 24 | $727.7M | $68.4M | ||
| Q2 24 | $713.3M | $62.1M | ||
| Q1 24 | $672.4M | $59.7M |
| Q4 25 | $1.6B | $557.6M | ||
| Q3 25 | $1.7B | $571.6M | ||
| Q2 25 | $1.6B | $570.2M | ||
| Q1 25 | $1.6B | $513.9M | ||
| Q4 24 | $1.6B | $475.9M | ||
| Q3 24 | $1.5B | $460.1M | ||
| Q2 24 | $1.5B | $429.3M | ||
| Q1 24 | $1.6B | $401.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $9.8M |
| Free Cash FlowOCF − Capex | $24.6M | $8.7M |
| FCF MarginFCF / Revenue | 13.4% | 3.4% |
| Capex IntensityCapex / Revenue | 4.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $9.8M | ||
| Q3 25 | $52.6M | $22.8M | ||
| Q2 25 | $35.6M | $-28.9M | ||
| Q1 25 | $35.1M | $-34.9M | ||
| Q4 24 | $29.0M | $5.5M | ||
| Q3 24 | $60.0M | $22.9M | ||
| Q2 24 | $69.1M | $39.0K | ||
| Q1 24 | $55.3M | $-9.3M |
| Q4 25 | $24.6M | $8.7M | ||
| Q3 25 | $47.2M | $21.4M | ||
| Q2 25 | $25.0M | $-31.1M | ||
| Q1 25 | $24.4M | $-35.9M | ||
| Q4 24 | $16.6M | $4.8M | ||
| Q3 24 | $46.2M | $22.3M | ||
| Q2 24 | $63.1M | $-2.1M | ||
| Q1 24 | $46.5M | $-9.7M |
| Q4 25 | 13.4% | 3.4% | ||
| Q3 25 | 24.6% | 8.2% | ||
| Q2 25 | 14.3% | -13.9% | ||
| Q1 25 | 14.3% | -16.0% | ||
| Q4 24 | 8.9% | 1.7% | ||
| Q3 24 | 24.1% | 8.0% | ||
| Q2 24 | 34.6% | -1.0% | ||
| Q1 24 | 27.1% | -5.1% |
| Q4 25 | 4.5% | 0.4% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 1.0% | ||
| Q1 24 | 5.1% | 0.2% |
| Q4 25 | 1.35× | 2.77× | ||
| Q3 25 | 3.03× | 10.70× | ||
| Q2 25 | 1.15× | -12.24× | ||
| Q1 25 | 1.39× | -13.01× | ||
| Q4 24 | 0.76× | 1.33× | ||
| Q3 24 | 1.48× | 4.28× | ||
| Q2 24 | 1.82× | 0.01× | ||
| Q1 24 | 1.28× | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
